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Abstract
Background: Influenza A, including avian influenza, is a major public health threat in developed and developing 
countries. Rapid and accurate detection is a key component of strategies to contain spread of infection, and the 
efficient diagnosis of influenza-like-illness is essential to protect health infrastructure in the event of a major influenza 
outbreak.
Methods: We developed a multiplexed PCR (MT-PCR) assay for the simultaneous diagnosis of respiratory viruses 
causing influenza-like illness, including the specific recognition of influenza A haemagglutinin subtypes H1, H3, and H5. 
We tested several hundred clinical specimens in two diagnostic reference laboratories and compared the results with 
standard techniques.
Results: The sensitivity and specificity of these assays was higher than individual assays based on direct antigen 
detection and standard PCR against a range of control templates and in several hundred clinical specimens. The MT-
PCR assays provided differential diagnoses as well as potentially useful quantitation of virus in clinical samples.
Conclusions: MT-PCR is a potentially powerful tool for the differential diagnosis of influenza-like illness in the clinical 
diagnostic laboratory.
Background
Approximately one billion cases of influenza occur
around the world every year, despite the availability of
effective vaccines. These are associated with an estimated
3-500 000 deaths and 3-5 million hospitalizations annu-
ally and impose a significant economic burden on even
the most developed countries [1,2].
In an epidemic or pandemic setting, the rapid differen-
tiation of influenza A from other influenza-like illness
(ILI) is essential for infection control and patient manage-
ment [3]. However, a relatively non-specific presentation
means that influenza cannot be reliably distinguished
from other ILI presenting in the autumn and winter sea-
sons, and currently available diagnostic systems lack both
the sensitivity and specificity required for efficient differ-
entiation of ILI at the health facility or triage station [4].
A variety of different diagnostic tests are available to
detect most common respiratory viruses, but there is still
an unmet need for rapid, sensitive and accurate diagnosis.
Commonly used conventional methods of virus culture,
serological testing or antigen detection by direct immun-
ofluorescence are reasonably sensitive, but relatively
complex and labour-intensive, and are generally too slow
to be clinically relevant [5]. Rapid antigen or "point-of-
care" tests are widely available for influenza and RSV [6-
8] and take only about 15-30 minutes to perform, but
their sensitivity is lower than nucleic acid testing
(NAT)[9,10].
Predictable oseltamivir resistance occurring within
outbreaks of certain influenza subtypes and the presence
of several co-circulating influenza A viruses of different
epidemic potential also makes subtyping particularly
valuable and this is not generally available in any of the
rapid methods. Here, we used the recently described MT-
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PCR method [11] to develop quantitative assays for the
most important causes of ILI and the identification of
Influenza A subtypes, and evaluate their performance in
two clinical laboratories.
Methods/Results
Clinical and control specimens
Combined nose and throat swabs collected at the Centre
for Infectious Diseases and Microbiology (CIDM, at
Westmead Hospital in Sydney) in the southern hemi-
sphere winter of 2006 and 2007 were used for initial assay
validation at the Centre For Immunology at St Vincents
Hospital in Sydney (CFI). Gamma-irradiated MDCK-tis-
sue culture extracts with known amounts of Indonesian
(Indo 05, Indonesia "clade 2") and Vietnamese (HN 3028,
Vietnam "clade 1") strains of H5N1 influenza A virus
were provided Australia-wide as control templates [12],
and we used these along with locally cultivated tissue cul-
ture extracts of H3N2 A/Fujian/114/2002-like and H1N1
A/New Caledonia/20/99-like Influenza A virus and B/
Shanghai/361/2002 Influenza B virus.
Immunofluorescence
This was performed using fluorescein-conjugated mono-
clonal antibodies (Chemicon International, Temecula,
CA, USA) against influenza A and B, RSV, adenoviruses,
and hPIV1-3 on acetone-fixed smears of material from
respiratory tract specimens, as indicated and as previ-
ously described [13].
DNA handling and sequencing
Nucleic acid was extracted from clinical specimens and
from tissue culture using the High Pure Viral RNA
Extraction kit (Roche Diagnostics GmbH, Mannheim,
Germany), eluting 200 μl of sample into 50 μl of elution
buffer. A negative control was extracted with every batch.
MT-PCR primers were designed with a modified version
of Primer 3 software [14], and were based on alignments
of available sequences deposited in GenBank (Table 1)
and of cDNA amplicons obtained from known virus iso-
lates at CIDM cloned into pGEM-T (Promega) as positive
controls. A nested reverse transcriptase polymerase
chain reaction (RT-PCR) was used to detect influenza A
and B and other respiratory viruses, as previously
described [13,15,16]. DNA sequences of all PCR ampli-
cons were determined as needed by cloning into pGEM-T
for M13 dye primer sequencing (Promega) and were
compared with known sequences using EclustalW
(ANGIS). The melt temperature, with a range of 1.5°C
either side of predicted Tm, was deemed acceptable if the
melt curve was normal sigmoidal. Verification of correct-
sized discrete amplicons derived in step 2 MT-PCR
assays was performed using a Bioanalyzer DNA separa-
tion chip (Agilent Technologies, Forest Hill, Victoria,
Australia), as previously described [11].
Multiplexed tandem PCR (MT-PCR)
This is a two-step assay using nested primer pairs in
which the first step involves a highly multiplexed reaction
to pre-amplify multiple targets for (typically, 15) cycles.
These are then aliquoted into individual reaction tubes
containing nested specific PCR primers as template for
the second step reaction [11] which was performed using
a liquid handling robotics system provided by AusDiag-
nostics Pty Ltd. (Sydney, Australia). Primer and artificial
internal control sequences are not shown due to com-
mercial confidentiality agreements with AusDiagnostics
Pty Ltd. The target regions are specified in Table 1, with
example sequences. The internal control is a contrived
sequence that does not appear in nature. No base pairing
redundancies were specified in any of the primers used.
Lyophilized primers and reagent kits were prepared at
CFI and sent to CIDM, and to the Institute of Medical
and Veterinary Science (IMVS, at Royal Adelaide Hospi-
tal in Adelaide), for further testing of clinical samples col-
lected during routine investigation of ILI outbreaks and
sporadic infection at these two referral centres. For MT-
PCR performance, a strip tube containing Step 1 multi-
plexed primers was placed in a thermal cycler, along with
a Gene-Disc containing lyophilised Step 2 reagents and
oil (for covering PCR reactions) on the robot deck. The
samples were directly added to the strip tube in the ther-
mal cycler. A software template for the reaction was then
selected and all operations for performing the Step 1 mul-
tiplexed preamplification, dilution and aliquoting into the
Step 2 reaction tubes in the Gene-Disc were performed
automatically. The Gene-Disc was then hermetically
sealed in a heat-sealer and Step 2 amplification carried
out in a Rotor-Gene RG6000 thermal cycler. At the end of
Step 2 the presence or absence of each target was auto-
matically called using a software routine (AusDiagnostics
Pty Ltd.) that compared melt temperature of the product
with expected values and checked the purity and quantity
against predetermined threshold values, and these were
all manually verified. The cycle threshold (Ct) is the num-
ber of cycles at the takeoff point of the amplification
curve (see Figure 1). Quantitation was by comparison
with the internal control, which was assigned an arbitrary
value of 10 000, chosen so that the lowest concentration
target detected had a value above "1". Concentration of
the final step 2 product was expressed relative to the con-
trol as previously described [11].
Assay development
Assays were developed to detect Influenza viruses A and
B (INF-A and INF-B), the Respiratory Syncytial Virus
(RSV), Rhinovirus (RV), and human Parainfluenza virus
type 3 (hPIV-3), and to identify Influenza A haemaggluti-
nin gene types H1 (not H1N1/09), H3 and H5 within a
multiplexed tandem PCR (MT-PCR) assay profile [11],Szewczuk et al. BMC Infectious Diseases 2010, 10:113
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using sequences available from strains in our laboratory
and lodged in GenBank, including the reference
sequences listed in Table 1. Multiplexed assays are gener-
ally configured so as to divide neatly into 72 (the number
of positions available in a standard step 2 template in the
RG6000 cycler), with no empty wells remaining. Primers
targeting the Influenza A haemagglutinin H5 gene (in
"Influenza profile 1") were replaced by primers targeting
the nucleoprotein gene of human Parainfluenza virus
type 3 (hPIV-3) in another assay ("profile 3"). All data
were deidentified; additional testing of laboratory sam-
ples was approved as a Quality Assurance activity by the
Sydney West Area Health Service Human Research Eth-
ics Committee
Specific identification of influenza and RSV in positive 
controls
Thirty-nine viral cell-culture extracts from stored clinical
isolates (including isolates identified as INF-A n = 5, INF-
B n = 2, RSV n = 1, RV n = 7, along with undifferentiated
picornavirus n = 4, and one each of hPIV-1, hPIV-3, coro-
navirus 229E, coronavirus OC43, hMPV, enterovirus EV-
68, adenovirus type 3 and adenovirus type 4) were tested
using Influenza Profile 1 (INF-A, INF-B, RV, RSV, H1,
H3, H5) in blinded fashion in the lab at which the assays
were developed (CFI). Signals were all normalised against
an internal control value of 10 000 arbitrary units. All
INF-B and RSV were detected only in the known control
samples and no positive signals for H5 were observed in
any sample nor in (water-only) controls, in triplicate
assays (data not shown). Detection of INF-A was 100%
sensitive and specific. Example (step 2) cycle and melt
curves are shown in Figures 1, 2, 3, 4, after 15 pre-amplifi-
cation cycles in Step 1.  Step 2 cycling and melt curves in
multiplex assays of gene targets specific for influenza A,
influenza B, respiratory syncytial virus (RSV), rhinovirus
(RV) and human para-influenza virus 3 (hPIV3) in Fig-
ures 1-5. In all panels, right and left colour schemes cor-
respond; black line: internal control; A: INF-A.
Specific detection of Influenza A haemagglutinin subtypes
To specifically examine INF-A subtype detection, we
tested serially diluted irradiated whole extracts and cell
culture supernatants of reference strains of H1N1, H3N2,
and Indonesian and Vietnamese H5N1 strains with Influ-
enza Profile 1 (Table 1), with the most diluted samples
containing only 1-10 copies of RNA virus/μl. Where one
haemagglutinin type gave a greater than 100-fold fluores-
cence signal than another after normalization against the
internal control, it was deemed the correct result.
Due to limited availability of control samples, only 2 μl
of eluate (equivalent to the same concentration of virus if
Table 1: Gene targets for MT-PCR respiratory virus profile 1.
assay gene target Example reference sequencesa
INF-A Influenza A nucleoprotein A/New York/392/2004(H3N2) [GenBank NC_007366-73]; A/Sydney/05/97(H3N2) [GenBank 
CY039082]; A/Puerto Rico/8/34(H1N1) [GenBank NC_002016-23]; A/New Caledonia/20/
99(H1N1) [GenBank AJ458265]; A/New Zealand/7/1983(H1N1) [GenBank CY020189-196]; A/
Indonesia/7/2005(H5N1) [GenBank EU146637]; A/Indonesia/175H/2005(H5N1) [GenBank 
EU146643]; A/Viet Nam/1203/2004(H5N1) [GenBank AY818038]; A/Viet Nam/1194/
2004(H5N1) [GenBank AY651498];
INF-B Influenza B nucleoprotein B/lee/40 [GenBank NC_002208.1]
H1 Influenza A haemagglutinin A/Puerto Rico/8/34(H1N1) [GenBank NC_002016-23]; A/New Caledonia/20/99(H1N1) 
[GenBank AJ344014] A/New Zealand/7/1983(H1N1) [GenBank CY020189-196]; A/Beijing/
262/95(H1N1) [GenBank EF541421];
H3 Influenza A haemagglutinin A/Sydney/5/1997(H3N2) [GenBank CY039079]; A/Fiji/185/2004(H3N2) [GenBank EF566069/
EH5041403]; A/New York/392/2004(H3N2) [GenBank NC_007366-73]; A/Aichi/2/68(H3N2) 
[GenBank AB295605]
H5b Influenza A haemagglutinin A/Viet Nam/LA-028/2005(H5N1) [GenBank DQ099782]c; A/Viet Nam/1203/2004(H5N1) 
[GenBank AY818135]c; A/Viet Nam/JP14/2005(H5N1) [GenBank EF456799]c; A/Viet Nam/
1194/2004(H5N1) [GenBank EF551402]c; A/Indonesia/7/2005(H5N1) [GenBank EU146632]d; 
A/Indonesia/175H/2005(H5N1) [GenBank EU146640]d; A/Indonesia/5/05(H5N1) [GenBank 
EF541394]d;
RSV Human Respiratory Syncytial Virus polymerase (L) [GenBank NC_001781.1] (nt8509-15009)
hPIV-3e Human Parainfluenza virus type 3 nucleocapsid [GenBank NC_001796.2] (nt111-1658)
RV Human Rhinovirus 5' untranscribed region (5'-UTR) [GenBank EU700020-28]
aNCBI reference sequences (NC_) cited where possible.
bInfluenza profile 3 does not include H5; c "clade 1" virus; d "clade 2" virus;
eInfluenza profile 1 does not include hPIV-3Szewczuk et al. BMC Infectious Diseases 2010, 10:113
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Figure 1 Cycling and melt curves for Influenza A H1 and H3
         
 
        
 
a. Influenza A H1N1 
b. Influenza A H3N2 
   
   H1   
       A  
   
     A   
        H3  
Figure 2 Cycling and melt curves for Influenza A H5 and Influenza B
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extraction efficiency was 100%) was used for analysis (5 μl
is recommended for extracted nasal pharyngeal samples)
and all assays in Table 2 were performed only once. Serial
ten-fold dilutions of H1 whole cell culture extracts from
10-1 down to 10-4 yielded specific signals for H1 (63904
down to 188 normalised units) and INF-A (67191 down
to 231) only. Similarly, serial dilutions of H3 whole cell
culture extracts from 10-1 down to 10-4 yielded specific
signals for H3 (33064 to 295) and INF-A (4734 to 15),
with only very low cross-reactivity with H1 in the least
diluted samples but with a 500-fold differential (e.g. H3 =
33064 and H1 = 66 at 10-1). H5-specific signal was
obtained from all but the highest dilutions (10-6) of whole
cell culture extracts, in which INF-A was detected at low
level. Low-level cross-reactivity (less than 1:200 relative
to H5) was observed with H1 (T able 2). The concentra-
tion of virus in H5N1 samples (shown in parentheses in
Table 2) had been previously determined [12] and were
detected at levels as low as a single copy of virus/μl in the
original sample in both strains.
Testing of MT-PCR assays with known clinical specimens
We next tested the same set of assays (Influenza Profile 1)
at CIDM on 5 ul of the nucleic acid extracts obtained
from forty-five clinical specimens retrieved from storage
Figure 3 Cycling and melt curves for Respiratory Syncytial Virus and Rhinovirus
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Figure 4 Cycling and melt curves for Parainfluenza virus type 3
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at -70 deg C, all of which had previously been collected
during investigation of influenza in an institution. Several
subjects had been taking the antiviral agent oseltamivir at
time of sampling. Some of these specimens had been
tested by IF, some by PCR and some by both methods.
All of 18 previously identified INF-A samples were rec-
ognised by the MT-PCR INF-A assay, normalised values
ranging from 9 to 68590. All of these were retrieved from
long-term storage, and template degradation was a signif-
icant possibility. Six of these could not be assigned a spe-
cific haemagglutinin subtype, and most of these latter (5/
6) had a normalised INF-A value < 30. All three known
INF-B samples and all eight RSV-positive samples were
correctly identified by MT-PCR, with normalised values
of 136-2379 and 4306-264304, respectively (data not
shown).
Thus, MT-PCR recognised all of the known positive
INF-A samples; previous RT-PCR on these extracts and
Table 2: Specific detection of haemagglutinin subtypes.
specimen H1 H3 H5 INF-A result
H1N1 (A/New Caledonia/20/99-like)
Cells 10-1 a63904 - - 67191 H1
Cells 10-2 4856 - - 8362 H1
Cells 10-3 2492 - - 3023 H1
Cells 10-4 188 - - 231 H1
H3N2 (A/Fijian/114/2002-like)
Cells 10-1 66 33064 - 4734 H3
Cells 10-2 - 6456 - 931 H3
Cells 10-3 - 1570 - 142 H3
Cells 10-4 -2 9 5 - 1 5 H 3
H5N1 (HN 3028 Vietnam; clade 1)
S/N 10-2 - - 97528 7 H5
S/N 10-3 1 - 865 3 H5
S/N 10-4 27 - 8490 25 H5
S/N 10-5 --- 1 2 ( I N F - A )
Cells 10-1 (104/μl) 2 - 133177 1 H5
Cells 10-2 (103/μl) 5 - 116490 2 H5
Cells 10-3 (102/μl) 2 - 49011 19 H5
Cells 10-4 (101/μl) 38 - 11836 128 H5
H5N1 (Indo 05 Indonesia; clade 2)
S/N 10-1 - - 2489082 - H5
S/N 10-2 30 - 167289 6 H5
S/N 10-3 4 - 143625 6 H5
S/N 10-4 - - 156819 5 H5
Cells 10-1 (104/μl)b - - 522949 - H5
Cells 10-2 (103/μl) - - 64783 6 H5
Cells 10-3 (102/μl) 37 - 194809 1431 H5
Cells 10-4 (101/μl) 72 - 16788 9 H5
Cells 10-5 (100/μl) 19 249234 7055 H5
Cells 10-6 (10-1/μl) 9 - - 234 (INF-A)
a values obtained after normalisation against internal control;
b copies of virus per μl in each original sample [12]
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IF results on original samples were all congruent where
both had been performed (Table 3). However, six of the
sixteen samples reported negative by IF for INF-A were
positive by MT-PCR (not shown). Of these six, one was
also weakly positive by RT-PCR for INF-A (but had been
reported as a negative result) and earlier specimens from
the same patients had been positive for INF-A in another
four cases. These additional INF-A detections were all
low-level (normalised result < 100) but all had correct-
sized discrete second-stage amplicons as determined on
Bioanalyzer (Agilent, SantaClara, CA) with sigmoidal
cycling curves and single melt peaks and are thought to
represent true positive results. Sequencing was per-
formed on all six of the unexpected positives to confirm
the results.
Of those that tested positive by MT-PCR, IF had
detected a significant pathogen in 14/22 (64%) and in-
house RT-PCR had previously detected 23/28 (82%).
Comparison of MT-PCR assays with immunofluorescence
For greater clinical utility in the Australian influenza sea-
son, we then replaced the H5 assay with an hPIV-3 assay
(Influenza profile 3: INF-A, INF-B, H1, H3, RSV, RV,
hPIV-3) and tested this profile independently in two clin-
ical laboratories (CIDM and IMVS) (Table 4).
Two hundred and seventy-six clinical specimens tested
by IF at the CIDM were tested by MT-PCR; congruent
results were obtained in 53/56 IF-positive specimens;
three of the 38 INF-A specimens were not detected by
MT-PCR. Two of these three could not be confirmed by
RT-PCR for INF-A either, suggesting a false-positive IF
result (no inhibition was detected).
220 additional specimens were negative by IF: 14 of
these samples were also positive by MT-PCR for INF-A
(and/or H3), one for INF-B, and five for RSV (these five
all coming from symptomatic patients taken during
investigation of an RSV outbreak). All of these 14 addi-
tional positive MT-PCR results were low-level (< 50 nor-
malised units). Two additional hPIV-3 and ten RSV were
also detected in samples that had only been tested for
INF-A and INF-B, but these are not included in Table 4.
Table 3: Comparison of IF and PCR with MT-PCR Influenza profile 1.
previous result  MT-PCR resulta
IF (total) 32
INF-A (unspecified) 6 6 (H3 n = 4; H1 n = 1)b
RSV 8 8
total INF-A/RSV 14 22 (14 + INF-A n = 8)c
total negative 18 10
PCR (total) 37
INF-A (unspecified) 17 17 (H3 n = 5; H1 n = 1)
INF-B 3 3
RSV 2 2
total INF-A/-B/RSV 23 28 (+ INF-A n = 5)
total negative 14 9
IF or PCR (total) 45
all INF-A 18 24
all INF-B 3 3
all RSV 8 8
all positive results 29 35
all negative results 16 10
aprofile 1 includes assays for INF-A, INF-B, H1, H3, H5, RSV and RV but not hPIV3; ball 6 were also PCR positive; cnot including INF-B (n = 3) 
detected by MT-PCR in samples which had not been tested for these pathogensSzewczuk et al. BMC Infectious Diseases 2010, 10:113
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Comparison of MT-PCR assays with standard RT-PCR
One hundred and seventy-six additional clinical speci-
mens, completely unrelated to those tested above, were
tested by RT-PCR at the IMVS [16]: 87 were reported
positive and MT-PCR results were congruent in all of
these (Table 4). Of the 89 negative results, five tested pos-
itive by MT-PCR (profile 3): one was a very low-level
INF-A, while the other four were RSV and RV. These
specimens had not previously been tested for these
pathogens and the MT-PCR results are not included in
Table 4. An INF-A/RSV co-infection which had been
already identified by RT-PCR was identified as an INF-A
H3/RSV co-infection by MT-PCR (not shown).
Relative quantities of influenza virus in clinical specimens
The quantitative nature of MT-PCR potentially allows the
c o m p a r i s o n  o f  n o r m a l i s e d  v a l u e s  o v e r  t i m e  b u t  s e r i a l
INF-A values alone may be misleading if the number of
cells in the sample (a measure of sample "quality") varies
significantly. Expressing the INF-A value as a function of
the normalised value of the human NONO (non-POU
domain containing, octamer-binding) gene (GenBank
Accession No. NC_000023.9) gives an approximation of
the amount of human epithelial cells harvested in sam-
pling. INF-A/NONO ratios derived from a small subset
of patients were assayed using the assays in Influenza
profile 4 (INF-A, INF-B, H1, H3, H5, RSV, RV, hPIV3 and
NONO) (Table 5). The set of INF-A/NONO ratios in
Table 5 were derived from assays of serial samples of
patients treated with oseltamivir for influenza A during
the course of management of an institutional outbreak,
demonstrating the potential for quantitation as a marker
of sample quality (normalised NONO value) and perhaps
of the course of infection (INF-A/NONO ratio).
Table 4: Comparison of IF and PCR with MT-PCR Influenza profile 3.
previous result  MT-PCR resulta
IF CIDM (total) 276
INF-A (unspecified) 38 35 (H3 n = 28)
INF-B 1 1
RSV 15 15
hPIV-3 3 3
total +ve 56 73 (53 +INF-A n = 14, INF-B n = 1, RSV n = 5)
-ve 220 b203
PCR IMVS (total) 176
INF-A (unspecified) 41 41 (H3 n = 27; H1 n = 9)
INF-B 13 13
RSV 22 22
hPIV-3 11 11
total +ve 87 88 (+INF-A n = 1)c
-ve 89 85
IF or PCR (total) 452
all INF-A 79 90 (3 IF +ves for INF-A not detected)
all INF-B 14 14
all RSV 37 37
all hPIV-3 14 14
all positive results 144 156 (+INF-A n = 15)
all negative results 308 b296
aprofile 3 includes assays for INF-A, INF-B, H1, H3, RSV, RV and hPIV3 but not H5; bnot including additional hPIV-3 (n = 2) or RSV (n = 10) 
detected by MT-PCR in samples which had not been tested for these pathogens; cnot including RSV/INF-A and RV/RSV co-infectionsSzewczuk et al. BMC Infectious Diseases 2010, 10:113
http://www.biomedcentral.com/1471-2334/10/113
Page 9 of 12
Discussion
Detection methods are available for the major ILI patho-
gens (Table 1), as well as for the 15 known H and 9 known
N variants [17-22]. Antigen-based rapid assays are gener-
ally quite specific but range from 60-70% in sensitivity
[6,8]; PCR methods appear to be the most sensitive and
specific, with detection limits down to < 0.1 TCID50/mL
[23-26]. Multiplex PCR must deal with the competition
and interference that arises as a result of using large num-
bers of primers simultaneously. DNA hybridisation after
multiplexed PCR is one solution but is slow and labour-
intensive [27,28]. MT-PCR deals with the problem by
stopping the multiplexed first round of amplification
before competition develops, then using the amplified
products as template for a second round of individual
specific 'nested' reactions [11].
This evaluation does not control for variation in speci-
men quality or operator performance or any of a number
of other variables applicable in real working laboratories.
We used an automated liquid-handling system and
r o b o t i c  c y c l e r  t h a t  o p e r a t e s  o n  a  p r e s e t  a l g o r i t h m  f o r
both cycling and for calling of results. All results were
manually verified in this study but required operator
expertise is otherwise minimal. Second-stage amplified
product is sealed and discarded unopened. Every second-
step 72-well gene disc has 12 wells for each target of a 6-
target assay, all separated spatially. The additional posi-
tives we describe came on different days, all with negative
controls and with several other negatives in the runs in
which they were detected. All MT-PCR reactions yielded
normal melt curves and all reactions giving unexpected
results also contained discrete correct-sized amplicons.
No multiple or unexpected-size amplicons or discrepant
melt temperatures were identified. Nevertheless,
sequencing of clinical isolates was not performed after
initial test validation and no additional alternative inde-
pendent testing was performed to specifically verify sec-
ond-step results, so contamination of the second-step
reaction with unrelated first-step amplicons cannot be
completely excluded.
The MT -PCR method is essentially a nested RT -PCR
and would therefore be expected to be more sensitive
than a conventional PCR or direct antigen detection sys-
tem [29]. Specificity may thus be underestimated if MT-
PCR detects target sequences in material below levels
detected by conventional methods. Testing of control
templates gave "clean" results with no evident cross-reac-
tion (Figures 1, 2, 3, 4) and the unexpected positive
results obtained in "negative" clinical specimens were
almost uniformly at low levels, consistent with this as an
explanation. Also consistent, unexpected additional posi-
tive results from MT-PCR were much more common in
specimens deemed negative by IF than by PCR (see Table
4). For example, the additional MT-PCR-positive IF-neg-
ative samples at CIDM (n = 14) for INF-A were collected
from symptomatic patients during an influenza outbreak
and several were either confirmed by RT-PCR or were
associated with seroconversion (greater than four-fold
increase) or initial high (> = 32) titres to Influenza A. This
level of additional positive results (~10%) is very similar
to that seen in previous reports for assays of this type
[30]. Taken all together and including assays tested within
both profiles, MT-PCR correctly identified 141 (97.9%) of
144 clinical specimens found positive by standard meth-
ods. Conversely, taking into account all of those speci-
mens found to be positive by MT-PCR in this study, IF
detected a significant pathogen in 56/73 (77%) and in-
house RT-PCRs detected 87/88 (99%). For influenza A
Table 5: Changing INF-A/NONO ratios in treated cases.
# day 0 day 3 day 6
a 6.7 92.8 61.9
b 139.8 43.3 6.4
c 900.0 666.7 0
d 21.2 4.2 0
e 26523.8 90.9 0
f 26.7 315.3 0
g 200.7 9.61 0
h 335.8 0.3 0
i 6854.5 5.5 3.5
j 6333.3 126.4 1.9
k 187071.4 52.6 1.2
l 6854.5 5.5 3.4
normalised ratios are shown, from day 0 (first contact with patient) to day 6; individual cases identified only as alphabetical letters.Szewczuk et al. BMC Infectious Diseases 2010, 10:113
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detection, this was a relative sensitivity of 38/49 (78%) for
IF and 41/42 (98%) for RT-PCR [16], compared to MT-
PCR.
IF and MT-PCR were entirely congruent in clinical
specimens tested for INF-B (n = 17), RSV (n = 44) and
hPIV-3 (n = 14). Of the three samples positive by IF but
negative by MT-PCR for INF-A, only one could be con-
firmed on repeat testing. If these false-positive IF results
are set aside, the MT-PCR sensitivity relative to any refer-
ence laboratory positive result would be recalculated as
141/142 (99.3%) and, if the 47 positive results obtained
from the 39 cell cultures and 22 additional controls in
Table 2 included, as 188/189 (99.5%). Conversely, the IF
detected 70/95 (74%) and RT-PCR detected 110/116
(95%) of those that were MT-PCR positive for any patho-
gen, which included many additional low-level positives.
For INF-A, the relative sensitivity overall of IF relative to
MT-PCR was 44/63 (70%) and of in-house RT-PCR was
58/64 (91%).
Human Influenza virus replicates throughout the respi-
ratory tract and viral loads normally peak (103 to 107
TCID50/mL of nasopharyngeal samples) at 24-72 hours
after onset of symptoms. Determining the infectious
period and its variability is crucial for individual and pub-
lic health planning but are likely to be both host- and
strain-specific [24,31,32]. In previous testing of RNA tar-
gets using MT-PCR, the correlation of quantitation over
two logs of template concentration was 0.99 and the coef-
ficient of variation over ten independent cycle threshold
(Ct) measurements was 0.03 [11]. Here, we also used
NONO as a marker of human epithelial cells in the speci-
men to normalise viral titres (Table 5). For well-collected
specimens with significant amounts of human epithelial
cells present, the INF-A/NONO ratio may be useful to
monitor viral shedding and infectivity.
However, actual primer sequences may fail to recognise
new viral variants and so a lack of transparency by manu-
facturers in releasing such information requires evidence
that the very latest sequences available are completely
homologous with the primers included, if clinical labora-
tories are to trust the assays. Given the ready availability
of influenza A sequences (eg. via PubMed), it is reason-
able to expect this as a minimum standard. Our testing of
fully-characterised strains included only those listed in
Table 2, and the reference sequences used are listed in
Table 1. In this study, the isolates tested in the clinical lab-
oratories came only from two Australian population cen-
tres and different regions may encounter strains which
are significantly different from those listed in Tables 1
and 2.
The initial H5 target is a consensus for clades 1-3 of the
highly pathogenic H5N1 strains, consistent with WHO
guidelines http://www.who.int/csr/disease/avian_influ-
enza/guidelines/RecAIlabtestsAug07.pdf, but the region
targeted by our consensus INF-A primers varies signifi-
cantly from that of the highly pathogenic avian strains of
Influenza A, and this was reflected in a relatively low sen-
sitivity in the INF-A assay for H5N1. Since this assay was
developed, we have also experienced the influenza A/
H1N1/09 pandemic, which caused a significant number
of intensive care admissions and deaths in this country
(33) and required modifications to include the NP gene of
A/H1N1/09 and an M gene consensus (H1N1; A/H1N1/
09; H3N2; H5N1). Performance in the Australian 2009
influenza season appears comparable to a nested RT-PCR
specifically optimised for A/H1N1/09 only [9,10].
The diagnosis of co-infections (e.g. RSV and INF-A)
and other causes of ILI may be clinically important. Pan-
demic influenza dramatically increases requirements for
high-level Intensive Care [33] and the ability to efficiently
distinguish true INF-A from ILI of a less threatening
nature in the context of an outbreak or epidemic may be
vital to minimise the burden on the health infrastructure
[34]. Respiratory syncytial virus (RSV) is the single most
important cause of acute lower respiratory tract diseases
including bronchiolitis and pneumonia in infants and
young children and may contribute to hundreds of thou-
sands of deaths annually among the elderly and immuno-
compromised [1,35,36]. Human Parainfluenza virus type
3 (hPIV-3) is associated with pharyngitis, bronchiolitis
and pneumonia in children, and respiratory infections in
adults and is the second most significant acute viral respi-
ratory tract infection in young children after RSV. Both
are leading causes of hospitalization in adults with acute
community-acquired respiratory disease. The rhinovi-
ruses (RV), of which there are more than 100 serotypes,
act either as single pathogens or in mixed infections, but
all of these may present as a non-specific ILI.
Conclusions
We have tested several hundred clinical samples in two
reference laboratories and found multiplexed tandem
(MT)-PCR to be comparable to target-specific RT-PCR
and a great deal more sensitive than direct immunofluo-
rescence for the detection of several of the most impor-
tant causative agents of influenza-like illness.
Importantly, this method simultaneously subtypes Influ-
enza A, identifies multiple pathogens and co-infections in
a single specimen and provides potentially valuable quan-
titative data. A multiplexed method also facilitates recog-
nition of co-circulating viruses in outbreak situations in
which they might otherwise be assumed identical. It is
clear that, as for influenza vaccine strategies, primer
designs need to be reviewed regularly in light of prevalent
sequence variations and the configuration of the multi-
plexed assay itself needs to be informed by the relevant
epidemiology of the region. The assay we describe pres-
ently costs around AUD$15 (USD$12) for 6 targetsSzewczuk et al. BMC Infectious Diseases 2010, 10:113
http://www.biomedcentral.com/1471-2334/10/113
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(~USD$2 per target). Even with additional purification
and labour costs, this is potentially cost-effective in the
routine laboratory.
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